Sone-026

SONE-026 refers to a specific entry in the Japanese adult video (JAV) industry, featuring the well-known actress Yua Mikami. Released under the S1 No. 1 Style label, this title is often cited as a standout performance from her earlier career. Title Overview

The film's theme focuses on a "high-class" or "forbidden" encounter, a common trope for Yua Mikami, who was frequently marketed as a top-tier idol-turned-actress. The production values are typical of the S1 label—high-definition cinematography, polished lighting, and a focus on aesthetic appeal. Key Details

Main Actress: Yua Mikami, a former member of the J-pop group SKE48 who became one of the most recognizable faces in the industry. SONE-026

Label: S1 No. 1 Style, known for its high-budget productions and exclusive contracts with top talent.

Release Context: This title was part of the momentum that established Yua as a "prestige" performer, focusing on her idol background and "perfect" visual presentation. Production Style SONE-026 refers to a specific entry in the

The "SONE" series often highlights the elegance of the actress. In SONE-026, the focus is on:

Visual Aesthetics: Close-ups and lighting designed to emphasize Yua's facial features and skin. Phase I: Designed to assess safety

Setting: Generally features upscale or domestic settings to fit the "luxury" idol persona.

Performance: Known for a mix of soft-core idol-style photography and the more explicit content expected from the S1 label.

Clinical development (assumed early-stage)

• Phase I: Designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and to define a recommended Phase II dose (RP2D). Typical endpoints include dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and preliminary anti-tumor activity.
• Biomarker strategy: Companion diagnostics may identify tumors with pathway activation or specific mutations predictive of response; pharmacodynamic biomarkers (e.g., decreased phosphorylation of downstream substrates) help confirm target engagement.

3.1. In‑vitro enzyme inhibition

| Isoform | IC₅₀ (nM) | Selectivity (vs PI3Kα) | |---------|-----------|------------------------| | PI3Kδ | 0.8 ± 0.1 | 250‑fold | | PI3Kγ | 1.2 ± 0.2 | 210‑fold | | PI3Kα | > 200 | — | | PI3Kβ | > 180 | — |

Enzyme assays were performed using recombinant human PI3K catalytic subunits (Eurofins DiscoverX) with a radiometric ADP‑Glo™ read‑out. SONE‑026 displayed reversible, ATP‑competitive inhibition confirmed by kinetic analysis (K_i ≈ 0.5 nM).

Preclinical data

• In vitro: Demonstrated low-nanomolar inhibition of kinase activity; reduced proliferation in a panel of cancer cell lines (notably lung, colorectal, and certain sarcomas).
• In vivo: Mouse xenograft models showed dose-dependent tumor growth delay and regression at tolerated doses; pharmacokinetics support once- or twice-daily oral dosing in animals.
• Toxicology: Repeat-dose studies identified target-organ effects at higher exposures (e.g., liver enzyme elevations and reversible hematologic changes), establishing a no-observed-adverse-effect level (NOAEL) guiding first-in-human dosing.